u 22

BU 224 hydrochloride 是一种选择性的咪唑啉 I(2) 结合位点配体，具有镇痛和抗抑郁样活性。

BU 226 hydrochloride 对咪唑啉受体具有亲和力，尤其是对 I2 结合位点，Ki 为 1.4 nM。 BU 226 hydrochloride 对 alpha 2-adrenoceptors 显示出低 (microM) 亲和力。

PNU 22394 hydrochloride 是一种 5-HT2C 激动剂和部分 5-HT2A 5-HT2B 激动剂。

AU-224 是一种可口服的苯甲酰胺衍生物，是一种强效的胃肠促动力活性。

KU-2285 对小鼠黑色素瘤 B16 显示出抗肿瘤、抗转移和抗集落形成作用。KU-2285 可用于研究胰腺癌。

BLU-222 是一种可口服且具有选择性的细胞周期蛋白依赖性激酶（CDK2） 抑制剂，具有抗肿瘤活性，可用于研究卵巢癌和子宫癌。

Deltamethrin (RU 22974) 是一种具有神经毒性的拟除虫菊酯杀虫剂，在大鼠中能够产生一系列可逆的运动症状(如包括后肢僵硬、舞蹈性关节炎)。

NU227326 是一种吲哚胺 2,3-双加氧酶 1 (IDO1) 的PROTAC降解剂，具备 DC50为 4.5 nM 的活性。在细胞系U87和GBM43中，NU227326 对 IDO1 的降解作用分别为 DC50 7.1 nM 和 11.8 nM。此化合物还展现出优异的药代动力学性质，血浆半衰期为 5.7 小时，脑组织半衰期为 11.8 小时。(Pink: ligand for target protein IDO1 ligand-1; Black: linker; Blue: ligand for E3 ligase Cereblon)

CPU-228 is a biochemicla.

Trimetaphan camsilate is a drug that counteracts cholinergic transmission at the ganglion type of nicotinic receptors of the autonomic ganglia and therefore blocks both the sympathetic nervous system and the parasympathetic nervous system. It acts as a non-depolarizing competitive antagonist at the nicotinic acetylcholine receptor, is short-acting, and is given intravenously.

NU223612 是一种有效的PROTAC(PROTACs)，可降解吲哚胺 2,3-双加氧酶 1 (IDO1) (Indoleamine 2,3-Dioxygenase (IDO))，Kd 为 640 nM。NU223612 通过CRBN 介导的蛋白酶体降解有效降解IDO1蛋白。NU223612 以 290 nM 的亲和力与 CRBN 结合。NU223612 可以穿过血脑屏障 (BBB)。

RWJ-56110 dihydrochloride is a potent, selective, peptide-mimetic inhibitor of PAR-1 activation and internalization (binding IC50=0.44 uM) and shows no effect on PAR-2, PAR-3, or PAR-4. RWJ-56110 dihydrochloride inhibits the aggregation of human platelets induced by both SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM), quite selective relative to U46619 . RWJ-56110 dihydrochloride blocks angiogenesis and blocks the formation of new vessels in vivo. RWJ-56110 dihydrochloride induces cell apoptosis[1][2]. Proteinase-activated receptors (PARs) are a family of G protein-coupled receptors activated by the proteolytic cleavage of their N-terminal extracellular domain, exposing a new amino terminal sequence that functions as a tethered ligand to activate the receptors.RWJ56110 inhibits the aggregation of human platelets induced by both SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM) while being quite selective relative to collagen and the thromboxane mimetic U46619 [1].RWJ-56110 dihydrochloride is fully inhibits thrombin-induced RASMC proliferation with an IC50 value of 3.5 μM. RWJ-56110 dihydrochloride shows blockade of thrombin's action with RASMC calcium mobilization (IC50=0.12 μM), as well as with HMVEC (IC50=0.13 μM) and HASMC calcium mobilization (IC50=0.17 μM)[1].RWJ56110 (0.1-10 μM; 24-96 hours) inhibits endothelial cell growth dose-dependently, with half-maximal inhibitory concentration of RWJ56110 is approximately 10 μM[2].RWJ56110 (0.1-10 μM; 6 hours) inhibits DNA synthesis of endothelial cells in a thymidine incorporation assays. Endothelial cells are in fast-growing state (50-60% confluence), RWJ56110 inhibits cell DNA synthesis in a dose-dependent manner, but when cells that are in the quiescent state (100% confluent), the inhibitory effect of PAR-1 antagonists is much less pronounced[2].RWJ56110 (0.1-10 μM; pretreatment for 15 min) inhibits thrombin-induced Erk1 2 activation in a concentration-dependent manner. However, when endothelial cells are stimulated by FBS (final concentration 4%), it reduces partially the activated levels of Erk1 2[2].RWJ56110 (30 μM; 24 hours) has an inhibitory effect on endothelial cell cycle progression. It reduces the percentage of cells in the S phase, while alterations in the percentages of G1 and G2 M cells are less pronounced[2]. Western Blot Analysis[2] Cell Line: Endothelial cells [1]. Andrade-Gordon, et al.Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. oc Natl Acad Sci U S A. 1999 Oct 26;96(22):12257-62. [2]. Panagiota Zania, et al. Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. J Pharmacol Exp Ther. 2006 Jul;318(1):246-54.

7-Methylguanosine 5’-diphosphate (7-Methyl-GDP) sodium, a cap analog, can be used in the synthesis of mRNA cap analogues[1]. 7-Methylguanosine 5’-diphosphate sodium inhibits binding of eukaryotic initiation factors to reovirus capped mRNA and complex formation involving uncapped mRNA or 18 S rRNA[1].T. brucei mRNA decapping enzyme (TbDcp2) that cleaves 7-Methylguanosine 5’-diphosphate sodium from capped RNA to generate pRNA, a substrate for TbCe1[2]. [1]. Sonenberg N, et al. Nonspecific effect of m7GMP on protein-RNA interactions. J Biol Chem. 1978;253(19):6630-6632.[2]. Ignatochkina AV, et al. The messenger RNA decapping and recapping pathway in Trypanosoma. Proc Natl Acad Sci U S A. 2015;112(22):6967-6972.

CAY10761 is an inhibitor of ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1; IC50s = 467 and 429 μM for the human and snake venom enzymes, respectively).1,2 It also inhibits mushroom tyrosinase (Ki = 1.9 μM) and urease from jack bean, P. mirabilis, and B. pasteurii (IC50s = 0.093, <0.125, and 0.089 mM, respectively, at pH 8.2).3,4 |1. Khan, K.M., Fatima, N., Rasheed, M., et al. 1,3,4-Oxadiazole-2(3H)-thione and its analogues: A new class of non-competitive nucleotide pyrophosphatases phosphodiesterases 1 inhibitors. Bioorg. Med. Chem. 17(22), 7816-7822 (2009).|2. Onyedibe, K.I., Wang, M., and Sintim, H.O. ENPP1, an old enzyme with new functions, and small molecule inhibitors - A STING in the tale of ENPP1. Molecules 24(22), E4192 (2019).|3. Ghani, U., and Ullah, N. New potent inhibitors of tyrosinase: Novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triazole-5(4H)-thiones, and substituted hydrazides to the dicopper active site. Bioorg. Med. Chem. 18(11), 4042-4048 (2010).|4. Amtul, Z., Rasheed, M., Choudhary, M.I., et al. Kinetics of novel competitive inhibitors of urease enzymes by a focused library of oxadiazoles thiadiazoles and triazoles. Biochem. Biophys. Res. Commun. 319(3), 1053-1063 (2004).